Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus type 1 (HIV-1) Gag-Pol, Env, and Nef-Tat-Vif represent a comprehensive collection of viral proteins essential for the replication, structural integrity, and pathogenesis of HIV-1 (UniProt P03366, P04578). The Gag polyprotein is responsible for viral assembly and budding, while the Pol polyprotein encodes critical enzymes including protease, reverse transcriptase, and integrase (UniProt P03366). The Env glycoprotein facilitates viral entry into host CD4+ T cells by binding to primary receptors and co-receptors (UniProt P04578). Regulatory and accessory proteins such as Nef, Tat, and Vif modulate host immune responses, enhance viral transcription, and counteract intrinsic cellular defense mechanisms (UniProt P03406, P04608, P03401). In the context of drug development, this multi-protein assembly is primarily utilized as a target for therapeutic and prophylactic vaccines, often delivered via DNA plasmids or viral vectors like Modified Vaccinia Ankara (MVA) (NIH NIAID). These immunotherapies, such as Pennvax-GP, aim to induce broad, multi-epitope T-cell and B-cell responses to control viral load and potentially eliminate the latent viral reservoir in infected individuals (ClinicalTrials.gov NCT02579252). While individual components like Protease or Reverse Transcriptase are targets for small-molecule antiretroviral drugs, the collective set is primarily a focus for immunotherapy and vaccine research.
Induction of multi-antigenic cellular and humoral immune responses against HIV-1
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 Gag-Pol, Envelope, and Nef-Tat-Vif proteins (HIV-1 Gag/Pol/Env/Nef/Tat/Vif).